Michael J. Farrell, Chairman and CEO of ResMed Inc., has reported a series of stock transactions in a recent SEC filing. These transactions involve performance-based restricted stock units that were earned based on the company's performance metrics. This move underscores Farrell's commitment to aligning his interests with those of the company and its shareholders.

ResMed Inc. is a leading player in the surgical and medical instruments industry, focusing on innovative solutions for patients with sleep apnea and chronic obstructive pulmonary disease (COPD). The company is publicly traded under the ticker symbol RMD and is incorporated in Delaware. Its business operations are based in San Diego, California.

According to the filing dated November 20, 2026, Farrell acquired 48,136 shares of ResMed common stock on November 19, 2026. Additionally, he disposed of 28,180.245 shares for tax withholding purposes related to the vesting of the performance-based restricted stock units granted on November 16, 2023. Following these transactions, Farrell holds a total of 519,910 shares directly and 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust.

This update may affect various stakeholders, including investors and employees, as it reflects the leadership's confidence in the company's future performance. The surgical and medical instruments industry may also see similar trends as executives engage in stock transactions that align with company performance metrics.

The filing does not say what happens next regarding further transactions or potential developments within the company.